Quantcast

Latest OSI Pharmaceuticals Stories

2009-12-17 10:30:00

WALTHAM, Mass., Dec. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom. The new Special European...

2009-10-20 05:00:00

NANJING, China, Oct. 20 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China. Headquartered in Long Island, OSI is a NASDAQ listed pharmaceutical company...

2009-05-28 07:00:00

WAYNE, N.J., EMERYVILLE, Calif. and MELVILLE, N.Y., May 28 /PRNewswire-FirstCall/ -- Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets in combination with Tarceva(R) (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer. The SEARCH (Sorafenib and...

2008-11-07 12:00:23

Genentech, a biotechnology company, and OSI Pharmaceuticals, have announced that a global Phase III study has met its primary endpoint and showed that Tarceva significantly extended the time patients with advanced non-small cell lung cancer lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo. Saturn is a placebo-controlled, randomized, double-blind, Phase III study conducted by Roche that enrolled...

2008-11-07 03:00:04

Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a global Phase III study (SATURN) met its primary endpoint and showed Tarceva(R) (erlotinib) significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo. There were no new or unexpected safety signals in the study and adverse...

2008-10-06 21:00:15

By ; wire Shares of South San Francisco-based Genentech dropped nearly 8 percent after the company announced with OSI Pharmaceuticals that a combination of two cancer drugs, Avastin with Tarceva, missed its primary goal in a clinical trial, failing to improve survival for patients with late-stage lung cancer. The trial focused on patients who had not responded to chemotherapy. But patients who were treated with Avastin and Tarceva did not survive significantly longer than those who were...

2008-10-06 15:00:41

Blockbuster cancer drug Avastin has suffered a setback, failing to improve overall survival when added to Tarceva in a Phase III trial for second-line advanced non-small cell lung cancer. However, there may still be a future for the drug combination within this indication, assuming data from a Phase III trial in the maintenance setting prove more positive. The Phase III study, known as BeTa Lung, was a randomized, double blinded study comparing the second-line combination of Avastin...

2008-10-06 09:00:09

Genentech and OSI Pharmaceuticals have announced that a randomized Phase III study evaluating Avastin in combination with Tarceva in patients with advanced non-small cell lung cancer whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo. However, there was clear evidence of clinical activity with improvements in the secondary endpoints of progression-free survival and...

2008-10-06 03:00:07

Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a randomized Phase III study (BeTa Lung) evaluating Avastin(R) (bevacizumab) in combination with Tarceva(R) (erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo. However, there was clear evidence of...

2008-09-09 15:00:09

Third Development Candidate that OSI has Moved into Clinical Development This Year OSI Pharmaceuticals, Inc. Kathy Galante (investors/media) Senior Director or Kim Wittig (media) Director 631-962-2000 or Burns McClellan, Inc. (representing OSI) Justin Jackson (media) Kathy Nugent (media) 212-213-0006 Logo: http://www.osip.com OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has initiated a first-in-human clinical study for its G-protein coupled...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related